User Name:      
Password:   

23-Feb-10 2:30 PM  CST  

New Funding Opportunities -- 2010 Ivy Awards 

The Ben and Catherine Ivy Foundation is interested in funding projects on the leading edge whose primary objective is to accomplish one or more of the following in a 12-month project period starting no later than July 2010:

 1. Enhance the output of a clinical trial for adults with GBM by performing correlative studies which significantly increase understanding of the biologic impact of a candidate therapeutic and/or interpretation of clinical response data.

2. Identify or validate predictors of therapeutic responsiveness by GBM molecular subtype that could potentially lead to patient stratification for therapy selection.

3. Determine preliminary efficacy of novel candidate therapies or validate novel therapeutic targets in GBM models.

 This RFP is open to early career investigators working in a non-profit or for-profit organization either in the U.S. or internationally. The maximum amount for a single one-year research project is $150,000. The deadline for applying is 03/22/2010. Application guidelines are available on the foundation website at www.ivyfoundation.org

Click a star to rate!

Rating: 0.00 / 5.00  - Not yet rated.
0 ratings


Add to Favorites
E-mail To A Friend E-mail this article to a friend (requires login).

 

For additional information on this Funding article, please contact:

Chas Haynes
(713) 526-0269

Source: The Ben and Catherine Ivy Foundation
http://www.ivyfoundation.org/

Related Documents:

Content Tags:

Tags: Funding Research

 

Other Recent Articles:

Return to Neurooncology, Society for Neuro-Oncology, Journal of Neurosurgery Articles Search

Support SNO in its mission to advance neuro-oncology research and education. Give today!

Levels of Support
President's Club

Donate Now!
Our Sponsors

Platinum Members:

American Brain Tumor Association Genentech Schering-Plough AMD Serono Pediatric Brain Tumor Foundation - Cure the Kids  The Sontag Foundation

 

Gold Members:

cernfoundation AstraZeneca Bristol-Myers Squibb